- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00536120
The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis
December 29, 2016 updated by: Biogen
A Randomized, Open-Label Study to Assess the Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis
The primary objectives of this study were: to evaluate the effect of Tysabri® (natalizumab) on antibody responses after immunization with a neoantigen (keyhole limpet hemocyanin [KLH]) and a recall antigen (tetanus toxoid [Td]), and to evaluate the effect of Tysabri on circulating lymphocyte subsets (CD3+, CD4+, CD8+, CD19+, and CD56+) over time in participants with relapsing forms of multiple sclerosis (MS).
The secondary objective was to assess alpha4-integrin saturation and alpha4-integrin expression levels over time.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Fullerton, California, United States, 92835
- Research Site 1
-
-
Colorado
-
Centennial, Colorado, United States, 80112
- Research Site
-
-
Michigan
-
Farmington Hills, Michigan, United States, 48334
- Research Site
-
-
New York
-
Patchogue, New York, United States, 11772
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28207
- Research Site 3
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73130
- Research Site 5
-
-
Tennessee
-
Franklin, Tennessee, United States, 37064
- Research Site
-
-
Texas
-
Dallas, Texas, United States, 75214
- Research Site
-
-
Washington
-
Seattle, Washington, United States, 98122
- Research Site 2
-
-
West Virginia
-
Charleston, West Virginia, United States, 25301
- Research Site 4
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- able to give written informed consent
- diagnosis of a relapsing form of MS and must fall within the therapeutic indication stated in the approved label for Tysabri
- aged 18-60 years, inclusive at the time of consent
- free of signs and symptoms suggestive of any serious opportunistic infection, based on medical history, physical examination, or laboratory testing
- must have a known history of tetanus toxoid immunization
Major Exclusion Criteria:
- tetanus toxoid vaccination less than 2 years prior to Screening
- known hypersensitivity to tetanus-diphtheria vaccine or KLH or any other administered vaccinations or their components (such as thimerosal)
- known allergy to shellfish
- history of active tuberculosis or undergoing treatment for tuberculosis
- previous exposure to KLH or vaccines containing KLH components (e.g., cancer vaccines)
- known history of human immunodeficiency virus (HIV), hepatitis C, or hepatitis B infection
- history of, or available abnormal laboratory results indicative of any significant disease
- history of malignancy
- history of organ transplantation (including anti-rejection therapy)
- history of severe allergic or anaphylactic reactions or known drug hypersensitivity
- a clinically significant infectious illness within 30 days prior to the Screening visit
- prior exposure to Tysabri, rituximab, any murine protein, or any therapeutic monoclonal antibody at any time
- receipt of intravenous (IV) or intramuscular (IM) immunoglobulin within 6 months of screening
- live virus, bacterial vaccines, or any other vaccines within 3 months of screening
- treatment with immunosuppressant medications within 6 months prior to screening
- treatment with cyclophosphamide within 1 year prior to screening
- treatment with immunomodulatory medications (interferon beta and glatiramer acetate) within 2 weeks prior to screening
- treatment with systemic corticosteroids within 4 weeks prior to screening
- treatment with any investigational product or approved therapy or vaccination for investigational use within 6 months prior to Screening
- women who are breastfeeding, pregnant, or planning to become pregnant during the study
- female subjects who are not postmenopausal for at least 1 year, surgically sterile (does not include tubal ligation), or willing to practice effective contraception during the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tysabri Plus Vaccinations
Participants receive 9 monthly doses of Tysabri 300 mg intravenous (IV), and receive vaccinations with neoantigen and recall antigen (keyhole limpet hemocyanin [KLH] and tetanus diphtheria toxoid [Td], according to manufacturer's prescribing information) at Month 6 (following the 7th dose of Tysabri) for both KLH and Td, and 14 and 28 days later for KLH.
|
Other Names:
KLH 1 mg administered subcutaneously (SC) in accordance with the Immucothel investigator's brochure.
Other Names:
Td administered in accordance with the manufacturer's prescribing information.
|
Other: Vaccinations Only
Participants receive only vaccinations with neoantigen and recall antigen (KLH and Td, according to manufacturer's prescribing information) at Month 0 for both KLH and Td, and 14 and 28 days later for KLH.
They do not receive any treatment for their MS and remain in the study through Month 2.
|
KLH 1 mg administered subcutaneously (SC) in accordance with the Immucothel investigator's brochure.
Other Names:
Td administered in accordance with the manufacturer's prescribing information.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Keyhole Limpet Hemocyanin (KLH) Responders at Day 28 Post-Vaccination
Time Frame: 28 days after immunization (Day 28 for Vaccinations Only Group/Day 196 for Tysabri Plus Vaccinations Group)
|
KLH responders were defined as those participants who had at least a 2-fold increase over pre-immunization level of anti-KLH antibodies in their blood at 28 days after vaccination with KLH.
|
28 days after immunization (Day 28 for Vaccinations Only Group/Day 196 for Tysabri Plus Vaccinations Group)
|
Percentage of Tetanus Diphtheria Toxoid (Td) Responders at Day 28 Post-Vaccination
Time Frame: 28 days after immunization (Day 28 for Vaccinations Only Group/Day 196 for Tysabri Plus Vaccinations Group)
|
Tetanus responders were defined as participants who had at least a 2-fold increase over pre-immunization levels of anti-tetanus antibodies in their blood at 28 days after they were immunized with tetanus.
|
28 days after immunization (Day 28 for Vaccinations Only Group/Day 196 for Tysabri Plus Vaccinations Group)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Percentage Change From Baseline in Circulating Lymphocyte Subsets CD3+, CD4+, CD8+, CD19+, and CD56+ at Month 3 of Tysabri Therapy
Time Frame: Month 0 (Baseline), Month 3
|
The effect of Tysabri on circulating lymphocyte subsets (CD3+, CD4+, CD8+, CD19+, and CD56+) was calculated as a percentage change from baseline pre-treatment values (based on absolute count).
|
Month 0 (Baseline), Month 3
|
Mean Percentage Change From Baseline in Circulating Lymphocyte Subsets CD3+, CD4+, CD8+, CD19+, and CD56+ at Month 6 of Tysabri Therapy
Time Frame: Month 0 (Baseline), Month 6
|
The effect of Tysabri on circulating lymphocyte subsets (CD3+, CD4+, CD8+, CD19+, and CD56+) was calculated as a percentage change from baseline pre-treatment values (based on absolute count).
|
Month 0 (Baseline), Month 6
|
Mean Alpha4-Integrin Saturation at Baseline, Month 3, and Month 6
Time Frame: Month 0 (Baseline), Month 3, and Month 6
|
Measurement of the degree of natalizumab saturation of the alpha4 integrin on peripheral blood mononuclear cells was accomplished by staining cells with phycoerythrin conjugated anti human IgG4 antibody (hIgG4-PE) to label the cell-bound natalizumab, followed by flow cytometric detection and quantification.
|
Month 0 (Baseline), Month 3, and Month 6
|
Mean Alpha4-Integrin Expression at Baseline, Month 3, and Month 6
Time Frame: Month 0 (Baseline), Month 3, and Month 6
|
Alpha4-integrin expression is the mean fluorescent intensity (MFI), a measure of fluorescence intensity often used to monitor changes in surface antigen modulation in flow cytometry.
There is no reference range for this test, which was developed at Biogen Idec.
|
Month 0 (Baseline), Month 3, and Month 6
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2008
Primary Completion (Actual)
November 1, 2009
Study Completion (Actual)
December 1, 2009
Study Registration Dates
First Submitted
September 25, 2007
First Submitted That Met QC Criteria
September 26, 2007
First Posted (Estimate)
September 27, 2007
Study Record Updates
Last Update Posted (Actual)
February 15, 2017
Last Update Submitted That Met QC Criteria
December 29, 2016
Last Verified
December 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Multiple Sclerosis
- Sclerosis
- Physiological Effects of Drugs
- Immunologic Factors
- Adjuvants, Immunologic
- Natalizumab
- Keyhole-limpet hemocyanin
Other Study ID Numbers
- 101MS404
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on BG00002 (natalizumab)
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisBelgium, Germany, Italy, Norway, France, Mexico, Australia, Spain, Portugal, Greece, Netherlands, United Kingdom, Czechia, Slovakia, Finland, Canada, Argentina, Brazil
-
BiogenCompletedAcute Ischemic StrokeSpain, United States, Germany, United Kingdom
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisCzechia, Belgium
-
BiogenTerminated
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisIreland
-
BiogenTerminatedSecondary Progressive Multiple SclerosisUnited States, Finland, Italy, Spain, Canada, France, Israel, Sweden, Netherlands, Belgium, Poland, United Kingdom, Czechia, Denmark, Russian Federation, Germany, Ireland
-
BiogenElan PharmaceuticalsCompleted
-
BiogenElan PharmaceuticalsCompletedRelapsing Remitting Multiple Sclerosis (RRMS)Belgium, Mexico, Poland, Romania, Saudi Arabia, Ukraine
-
BiogenCompletedRelapsing Multiple SclerosisUnited States, Puerto Rico
-
BiogenTerminatedRelapsing Multiple SclerosisUnited States